OBJECTIVE: Antiretroviral drugs can prevent mother-to-child transmission of HIV infection, but in-utero antiretroviral exposure may be associated with neurologic symptoms due to mitochondrial toxicity. We sought to identify the currently recommended regimen to prevent mother-to-child transmission that optimally balances risks of pediatric HIV infection and neurologic mitochondrial toxicity. DESIGN: Published MTCT and mitochondrial toxicity data were used in a decision analytic model of MTCT among women in sub-Saharan Africa. METHODS: We investigated the HIV and mitochondrial toxicity risks associated with no antiretroviral prophylaxis and five recommended regimens ranging from single-dose nevirapine to three-drug antiretroviral therapy (ART). Sensitivity analyses varied all parameters, including infant feeding strategy and the disability of mitochondrial toxicity relative to HIV. RESULTS: Provision of no antiretroviral drugs is the least effective and least toxic strategy, with 18-month HIV risk of 30.4% and mitochondrial toxicity risk of 0.2% (breastfed infants). With increasing drug number and duration, HIV risk decreases markedly (to 4.9% with three-drug ART), but mitochondrial toxicity risk also increases (to 2.2%, also with three-drug ART). Despite increased toxicity, three-drug ART minimizes total adverse pediatric outcomes (HIV plus mitochondrial toxicity), unless the highest published risks are true for both HIV and mitochondrial toxicity, or the disability from mitochondrial toxicity exceeds 6.4 times that of HIV infection. CONCLUSION: The risk of pediatric mitochondrial toxicity from effective regimens to prevent mother-to-child transmission is at least an order of magnitude lower than the risk of HIV infection associated with less-effective regimens. Concern regarding mitochondrial toxicity should not currently limit the use of three-drug ART to prevent mother-to-child transmission where it is available.
OBJECTIVE: Antiretroviral drugs can prevent mother-to-child transmission of HIV infection, but in-utero antiretroviral exposure may be associated with neurologic symptoms due to mitochondrial toxicity. We sought to identify the currently recommended regimen to prevent mother-to-child transmission that optimally balances risks of pediatric HIV infection and neurologic mitochondrial toxicity. DESIGN: Published MTCT and mitochondrial toxicity data were used in a decision analytic model of MTCT among women in sub-Saharan Africa. METHODS: We investigated the HIV and mitochondrial toxicity risks associated with no antiretroviral prophylaxis and five recommended regimens ranging from single-dose nevirapine to three-drug antiretroviral therapy (ART). Sensitivity analyses varied all parameters, including infant feeding strategy and the disability of mitochondrial toxicity relative to HIV. RESULTS: Provision of no antiretroviral drugs is the least effective and least toxic strategy, with 18-month HIV risk of 30.4% and mitochondrial toxicity risk of 0.2% (breastfed infants). With increasing drug number and duration, HIV risk decreases markedly (to 4.9% with three-drug ART), but mitochondrial toxicity risk also increases (to 2.2%, also with three-drug ART). Despite increased toxicity, three-drug ART minimizes total adverse pediatric outcomes (HIV plus mitochondrial toxicity), unless the highest published risks are true for both HIV and mitochondrial toxicity, or the disability from mitochondrial toxicity exceeds 6.4 times that of HIV infection. CONCLUSION: The risk of pediatric mitochondrial toxicity from effective regimens to prevent mother-to-child transmission is at least an order of magnitude lower than the risk of HIV infection associated with less-effective regimens. Concern regarding mitochondrial toxicity should not currently limit the use of three-drug ART to prevent mother-to-child transmission where it is available.
Authors: Rao L Divi; Kathryn J Haverkos; Juliette A Humsi; Marie E Shockley; Chandrasekhar Thamire; Kunio Nagashima; Ofelia A Olivero; Miriam C Poirier Journal: Environ Mol Mutagen Date: 2007 Apr-May Impact factor: 3.216
Authors: Ibou Thior; Shahin Lockman; Laura M Smeaton; Roger L Shapiro; Carolyn Wester; S Jody Heymann; Peter B Gilbert; Lisa Stevens; Trevor Peter; Soyeon Kim; Erik van Widenfelt; Claire Moffat; Patrick Ndase; Peter Arimi; Poloko Kebaabetswe; Patson Mazonde; Joseph Makhema; Kenneth McIntosh; Vladimir Novitsky; Tun-Hou Lee; Richard Marlink; Stephen Lagakos; Max Essex Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: M Lallemant; G Jourdain; S Le Coeur; S Kim; S Koetsawang; A M Comeau; W Phoolcharoen; M Essex; K McIntosh; V Vithayasai Journal: N Engl J Med Date: 2000-10-05 Impact factor: 91.245
Authors: Antoni Noguera; Claudia Fortuny; Carmen Muñoz-Almagro; Emilia Sanchez; M Antonia Vilaseca; Rafael Artuch; Jordi Pou; Rafael Jimenez Journal: Pediatrics Date: 2004-10-18 Impact factor: 7.124
Authors: Valériane Leroy; Charlotte Sakarovitch; Mario Cortina-Borja; James McIntyre; Hoosen Coovadia; Francois Dabis; Marie-Louise Newell; J Saba; G Gray; Ch Ndugwa; Ch Kilewo; A Massawe; P Kituuka; P Okong; A Grulich; H von Briesen; J Goudsmit; G Biberfeld; G Haverkamp; G J Weverling; J M A Lange Journal: AIDS Date: 2005-11-04 Impact factor: 4.177
Authors: Anna Coutsoudis; Francois Dabis; Wafaie Fawzi; Philippe Gaillard; Geert Haverkamp; D Robert Harris; J Brooks Jackson; Valerie Leroy; Nicolas Meda; Philippe Msellati; Marie-Louise Newell; Ruth Nsuati; Jennifer S Read; Stefan Wiktor Journal: J Infect Dis Date: 2004-05-26 Impact factor: 5.226
Authors: Carmen J Marsit; Sean S Brummel; Deborah Kacanek; George R Seage; Stephen A Spector; David A Armstrong; Barry M Lester; Kenneth Rich Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Sumona Chaudhury; Gloria K Mayondi; Paige L Williams; Jean Leidner; Roger Shapiro; Modiegi Diseko; Gbolahan Ajibola; Penny Holding; Vicki Tepper; Joseph Makhema; Chipo Petlo; George R Seage; Shahin Lockman; Betsy Kammerer Journal: AIDS Date: 2018-06-01 Impact factor: 4.177
Authors: Patricia A Sirois; Yanling Huo; Paige L Williams; Kathleen Malee; Patricia A Garvie; Betsy Kammerer; Kenneth Rich; Russell B Van Dyke; Molly L Nozyce Journal: Pediatr Infect Dis J Date: 2013-06 Impact factor: 2.129
Authors: Andrea L Ciaranello; Freddy Perez; Matthews Maruva; Jennifer Chu; Barbara Engelsmann; Jo Keatinge; Rochelle P Walensky; Angela Mushavi; Rumbidzai Mugwagwa; Francois Dabis; Kenneth A Freedberg Journal: PLoS One Date: 2011-06-02 Impact factor: 3.240
Authors: Andrea L Ciaranello; Freddy Perez; Jo Keatinge; Ji-Eun Park; Barbara Engelsmann; Matthews Maruva; Rochelle P Walensky; Francois Dabis; Jennifer Chu; Asinath Rusibamayila; Angela Mushavi; Kenneth A Freedberg Journal: PLoS Med Date: 2012-01-10 Impact factor: 11.069